Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J's 2Q Pharma Sales Up 17% | Contract Pharma

What are you searching for?

Sign in
Financial News

J&J’s 2Q Pharma Sales Up 17%

STELARA and DARZALEX sales drive growth with sales up 34% to $2.3 billion and up 59% to $1.4 billion in the quarter, respectively.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
2Q Revenues: $23.3 billion (+27%)
2Q Earnings: $6.3 billion (+73%)
Comments: Pharmaceutical sales were up 17% to $12.6 billion in the quarter, driven by STELARA for the treatment of immune-mediated inflammatory diseases, up 34% to $2.3 billion; DARZALEX for the treatment of multiple myeloma, up 59% to $1.4 billion; TREMFYA (guselkumab) for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis, up 40% to $479 million; ERLEADA (apalutamide), for the treatment of prostate cancer, up 78% to $302 million; IMBRUVICA (ibrutinib) for treating certain B-cell malignancies, up 18% to $1.1 billion; and INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), for the treatment of schizophrenia, up 18% to $1.0 billion. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for a number of immune-mediated inflammatory diseases, down 5% to $888 million. R&D expenses were up 25% to $3.4 billion. RYBREVANT (amivantamab-vmjw) received U.S. FDA approval as the first targeted treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) received U.S. FDA approval for combination with Pomalidomide and Dexamethasone for patients with Multiple Myeloma after first or subsequent relapse.

Read Contract Pharma’s Top Companies Report on J&J.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters